4d Molecular Therapeutics, Inc. · NASDAQ:FDMT

4d Molecular Therapeutics — Technical Presentation (May 2026)

12 slides from 4d Molecular Therapeutics's technical presentation, May 2026

  1. Slide 1: 2-Year Follow-Up: PRISM Phase 2b Clinical Trial of 4D-150 in nAMD

    2-Year Follow-Up: PRISM Phase 2b Clinical Trial Evaluating Investigational 4D-150, an Intravitreal Gene Therapy, in a Broad Neovascular AMD Population First-time data release Carl C. Awh, MD, FASRS Tennessee Retina Nashville, TN On behalf of the PRISM study investigators

  2. Slide 2: Disclosures

    Disclosures Consultant: Bausch + Lomb, Genentech, Inc., Ocular Therapeutix, Zeiss Royalties: Bausch + Lomb, Harrow, Katalyst Surgical/Zeiss Speakers Bureau: Genentech, Inc. Investigator: 4D Molecular Therapeutics, Adverum, Allergan, Apellis, Astellas/AIRM, Aura, Aviceda, Chengdu, Kanghong, Cognition

  3. Slide 3: 4D-150: A Novel, R100-Based Dual-Transgene Investigational Gene Therapy

    4D-150: A Novel, R100-Based Dual-Transgene Investigational Gene Therapy Delivery Vehicle: AAV Capsid (R100) Dual Transgene Payload: 4D-150 R100 AAV Capsid Specifically Designed via Therapeutic Vector Evolution for: Administration by routine intravitreal injection Crossing of vitreoretinal barriers S

  4. Slide 4: PRISM Clinical Trial: Focus on Phase 2b Cohort

    PRISM Clinical Trial: Focus on Phase 2b Cohort Evaluation of 4D-150 in a Broad Range of nAMD Populations Phase 1/2a Phase 2b Phase 3 Dose 3E10 vg/eye (N) 24 30 Severe, Population Broad Recalcitrant Mean Injections in Last 12 Months 10.2 4.4 Mean CST 425 µm 336 µm Mean Time Since Diagnosis 3.7 years

  5. Slide 5: Stable Anatomy and Visual Acuity Through 2 Years in nAMD Population

    A Single Intravitreal Dose of 4D-150 is Associated with Stable Anatomy and Visual Acuity Through 2 Years in a Broad nAMD Population Central Subfield Thickness 150 3E10 vg/eye (n=30) 1E10 vg/eye (n=15) Mean ±SD Change from BL 100 in CST (µm) 50 0 -50 -100 -150 -4 0 4 8 12 16 20 24 28 32 36 40 44 48 5

  6. Slide 6: Single Dose of 4D-150 Associated with Treatment Burden Reduction

    A Single Dose of 4D-150 is Associated with Treatment Burden Reduction in a Broad nAMD Population over 2 Years >50% of Participants Required 0-1 Supplemental Injection 15 Mean cumulative number 12 of injections 10 69% 78% 5 3.7 2.7 0 Projected* 4D-150 4D-150 2Q8W 1E10 3E10 AFLB vg/eye vg/eye Data cut

  7. Slide 7: PRISM Clinical Trial: Focus on Phase 2b Cohort

    PRISM Clinical Trial: Focus on Phase 2b Cohort Evaluation of 4D-150 in a Broad Range of nAMD Populations Phase 2b Phase 1/2a Phase 2b Subgroup Phase 3 Dose 3E10 vg/eye (N) 24 30 15 Severe, Recently Population Broad Recalcitrant Diagnosed Mean Injections in Last 12 Months 10.2 4.4 2.7 Mean CST 425 µm

  8. Slide 8: Stable Anatomy and Visual Acuity Through 2 Years in Recently Diagnosed nAMD

    A Single Intravitreal Dose of 4D-150 is Associated with Stable Anatomy and Visual Acuity Through 2 Years in a Recently Diagnosed* nAMD Population Central Subfield Thickness 150 3E10 vg/eye (n=15) 1E10 vg/eye (n=11) Mean ±SD Change from BL 100 50 in CST (µm) 0 -50 -100 -150 -4 0 4 8 12 16 20 24 28 32

  9. Slide 9: Treatment Burden Reduction in a Recently Diagnosed nAMD Population

    A Single Dose of 4D-150 is Associated with Treatment Burden Reduction in a Recently Diagnosed* nAMD Population over 2 Years 66% of Participants were Supplemental Injection-Free 15 Mean cumulative number 12 of injections 10 73% 87% 5 3.3 1.6 0 Projected† 4D-150 4D-150 2Q8W 1E10 3E10 AFLB vg/eye vg/ey

  10. Slide 10: PRISM Phase 1/2 Consistent and Predictable Intraocular Inflammation Profile

    PRISM Phase 1/2 Follow-up Suggests a Consistent and Predictable Intraocular Inflammation Profile Highest SUN/NEI Score† with 4D-150 3E10 vg/eye (N=71) Through Week 28 After Week 28 to Year 1 to 2 Year 2 to 4+ None 1+ Year 1 2+ Prophylactic corticosteroid (~20 weeks) 3+ 4+ ▪ No 4D-150–related serious

  11. Slide 11: Conclusions: PRISM Clinical Trial Long-Term Results

    Conclusions: PRISM Clinical Trial Long-Term Results 2-Year Efficacy Data: Phase 2b ▪ Visual acuity & anatomic control maintained ▪ Clear and consistent dose-response, consistent with all 4D-150 trials to date ▪ Consistent treatment burden reduction through 2 years†: 4D-150 Demonstrated Treatment Bur

  12. Slide 12: Thank you to all trial investigators, research staff, patients, and caregivers

    Thank you to all trial investigators, research staff, patients, and caregivers who contributed to this work! 12

4D Molecular Therapeutics — Technical Presentation (May 2026) on 6ix